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Abstract
The aim was to compare the diagnosis of COPD among smokers according to different
international guidelines and to compare the outcome when using slow (SVC) and forced vital
capacity (FVC).
In order to find current smokers a questionnaire was sent to persons who had been on sick leave
for more than two weeks. Those who smoked more than 8 cigarettes per day were invited to
perform a spirometry.
Totally 3,887 spirometries were performed. In this sample 10.2% fulfilled the NICE COPD-criteria,
14.0% the GOLD COPD-criteria and 21.7% the ERS COPD criteria. The diagnosis according to
NICE and GOLD guidelines is based on FVC and in the ERS guidelines the best value of either SVC
or FVC is used. Thus, substantially more subjects with COPD were found when the best of either
SVC or FVC was used. Forced VC tended to be higher than SVC when lung function was normal
and in those with mild obstruction prior to bronchodilatation whereas SVC exceeded FVC after
bronchodilatation in those who had severe bronchial obstruction.
The diagnosis of COPD is highly depending on which guidelines are used for defining the disease.
If FVC and not the best of SVC and FVC is used when defining COPD the diagnosis will be missed
in a substantial number of patients.
Background
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality amongst
the adult population worldwide [1]. Spirometry is the
gold standard for diagnosing and monitoring progression
of COPD [2] which is defined by irreversible lung func-
tion impairment with a reduced FEV1/vital capacity (VC)
ratio. However, differences in the definition of COPD in
guidelines and consensus statements make it difficult to
quantify the morbidity and to make comparisons between
countries. In addition, there are different recommenda-
tions in the major guidelines and consensus statements
concerning how to perform spirometry [2-4].
In the present study smokers were identified among
patients being on sick leave registered in a Swedish data-
base (Collective Bargaining Goup Sickness Insurance).
The smokers were invited to perform a spirometry and the
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aim of the study was to determine the prevalence of
COPD using the definitions and recommendations from
the European Respiratory Society (ERS) from 1995, the
National Institute for Clinical Excellence (NICE) guide-
lines and the National Heart, Lung, and Blood Institute
(NHLBI)/World Health Organization (WHO) Global Ini-
tiative for Chronic Obstructive Lung Disease (GOLD). A
further aim was to compare the number of subjects with
COPD when the COPD diagnosis was based on slow
(SVC) or forced vital capacity (FVC) when defining airway
obstruction (FEV1/VC).
Methods
In order to identify current smokers for a smoking cessa-
tion programme a questionnaire containing questions on
smoking habits was sent to persons 40 to 60 years of age,
who had been on sick leave, regardless of cause, for more
than two weeks. The persons were identified using the
database from the Collective Bargaining Goup Sickness
Insurance, AGS (in Swedish: Avtalsgruppsjukförsäkring)
[5]. The questionnaire was sent to all persons registered in
AGS during the period 1 April 1998 to 30 November
2000. To find persons with a potential risk of having
COPD those who, according to the questionnaire, cur-
rently smoked more than eight cigarettes per day were
invited to perform a spirometry.
Lung function testing was performed at ten different labo-
ratories by experienced and specially trained technicians.
Regular meetings were held to reinforce the recom-
mended techniques. Spirometry was performed according
to the ATS recommendations [6] with a few modifica-
tions. The spirometry was performed in the sitting posi-
tion and a nose clip was used. After 2 – 3 slow expiratory
vital capacity measurements, at least three forced expira-
tions were performed. Spirometry was performed before
and, in a selected group of patients, 15 minutes after inha-
lation of salbutamol dry powder (0.8 mg Ventolin™ Dis-
cus™, GlaxoWellcome). Reversibility test was only
performed in those who, prior to bronchodilatation, had
a SVC/FEV1 or FVC/FEV1 below 0.75. Short acting bron-
chodilator medication was withheld four hours and long
acting bronchodilators twelve hours before the reversibil-
ity testing. European reference values were used [7].
Definitions
The definitions and recommendations for defining COPD
from the ERS consensus statement from 1995 [4], the
NICE guideline [3], and the GOLD guidelines [2] were
used to calculate the prevalence of COPD (table 1). In the
NICE guidelines a FEV1  < 80% of predicted value is
required for a COPD diagnosis. To fulfil the COPD defini-
tion according to the ERS guidelines FEV1/VC has to be <
88% (men) or < 89% (women) of predicted value
whereas a FEV1/VC ratio < 0.7 is required in NICE and
GOLD recommendations. InNICE and GOLD guidelines
only FVC is used while the best of FVC and SVC is used in
the ERS recommendations. The ATS/ERS standards pub-
lished in 2004 [2] are identical to the GOLD guidelines in
this context and are therefore not specifically considered.
In the present study lung function was calculated after
bronchodilatation, according to NICE, ERS and GOLD
guidelines and FEV1/VC ratio was calculated by using only
FVC or the best out of FVC and SVC. The study was
approved by the Ethics Committee at Karolinska Insti-
tutet, Stockholm (reg.no. 98:044).
Results
During the study period 46,734 sick leave periods were
registered in the AGS in the selected geographical areas for
persons 40 to 60 years of age. Of these 2,841 were multi-
ple sick leave periods, 47 persons were deceased and 62
persons had either unknown or secret addresses. The
questionnaire was sent to the remaining 43,784 subjects.
The initial response rate was 55% and after two reminders
the response rate was 86%. Of the 37,571 responses, 90%
(33,765) were complete and of those daily smoking was
reported by 26% (8,929) of whom 83% (7,386) smoked
more than 8 cigarettes per day. Of those, 5,337 accepted
to undergo lung function testing. For different reasons
(mental disorder, n = 363, malignant tumor, n = 87, abuse
of alcohol or drugs, n = 40, could not speak, write or
understand Swedish, n = 22, other complicated illness,
such as recent myocardial infarction, n = 16) 528 patients
were excluded from the lung function testing. Of the
4,809 subjects invited to spirometry 3,887 completed the
examination. The reasons for not participating were:
already stopped smoking (n = 22), other illness such as
hernia, facial paralysis, low back pain, alcohol abuse (n =
Table 1: Definitions of COPD according to the ERS consensus statement, the NICE and the GOLD guidelines.
FEV1/(VC or FVC) FEV1 Remarks
ERS < 88% pred for men  Only for staging
< 89% pred for women
NICE < 70% absolute value < 80% predicted
GOLD < 70% absolute value Only for staging Post-bronchodilator valuesRespiratory Research 2007, 8:89 http://respiratory-research.com/content/8/1/89
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21), moved from the area (n = 8), deceased (n = 4), not
acceptable technique (n = 4), lost interest or not stating a
reason (n = 863). The selection procedure is shown in (fig-
ure 1).
Of those who completed spirometry 1,763 (45.4%) were
men, 51.6 (46.2 – 56.1) years of age (median and 25th -
75th percentiles), and 2124 (54.6%) were women, 50.8
(46.2 – 56.1) years of age.
In this group of 3887 subjects who smoked more than 8
cigarettes per day 10.2% had COPD according to NICE
criteria and 14.0% had COPD according to GOLD criteria.
According to these criteria only FVC is used to calculate
FEV1/FVC ratio. This means that 3.8% (148 individuals)
with mild COPD were identified according to the GOLD
guidelines but missed when the the NICE-guidelines, i e
when the diagnosis of COPD requires FEV1< 80% of pre-
dicted value, were used. When using the ERS recommen-
dations, using best value of SVC or FVC when calculating
FEV1/VC ratio the prevalence of COPD was 21.7% (table
2).
Prior to bronchodilatation FVC was higher than SVC in
the total groups of smokers (n = 3887) whereas the oppo-
site was the case in those 1577 subjects who had a pre-
bronchodilator FEV1/VC-ratio below 0.75 (figure 2).
Bronchodilatation abolished this difference (figure 2).
There was a fair, but not excellent, correlation (r = 0.57)
between the difference between SVC and FVC corrected
for the VC level when pre- and post-bronchodilator values
were compared (figure 3). Pre-bronchodilator SVC was
higher than FVC in those with the lowest pre-bronchodi-
lator FEV1 while the opposite was found in those with nor-
mal FEV1  (figure 4A). This was obvious prior to
bronchodilatation (total group) but remained when anal-
yses of post-bronchodilator values were analysed in those
with a pre-bronchodilator FEV1/VC ratio below 0.75 (fig-
ure 4B).
Discussion
In the present study of almost 4000 smokers, smoking
more than 8 cigarettes per day, it was demonstrated that
the prevalence of COPD differed depending on which
guidelines are used and whether the best of slow and
forced VC or only FVC were used. It was also shown that
Number of participants in each step of the study Figure 1
Number of participants in each step of the study.
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Accepted spirometry
Smoking >8 cig per day
Daily smokers
Included in the analysis
Responded to the questionnaire
Study group, questionnaire part
Number
4 809
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FVC exceeded SVC in persons with normal lung function
as assessed by spirometry wheras the opposite was found
in patients with impaired lung function. Inhalation of a
bronchodilator attenuated, but did not abolish, the effect
of lung function impairment on the difference between
SVC and FVC.
The definition of COPD is arbitrary and varies between
different consensus statements and guidelines. In the
present study the number of smokers, 40–60 years of age,
who got COPD diagnosis varied with a factor two (from
10% to 22%) depending on what definition was used.
This variation exceeds somewhat was recently was demon-
strated in an epidemiological setting which, based on a
random sample of 666 subjects, demonstrated prevalence
figures of 7.6 – 14.1% when defining COPD according to
different recommendations. [8]. The COPD diagnosis was
Relationship between pre- and post-bronchodilator slow  (SVC) and forced (FVC) vital capacity corrected for VC-level  in 1577 smokers with a pre-bronchodilator FEV1/VC -ratio  below 0.75 Figure 3
Relationship between pre- and post-bronchodilator slow 
(SVC) and forced (FVC) vital capacity corrected for VC-level 
in 1577 smokers with a pre-bronchodilator FEV1/VC -ratio 
below 0.75.
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Table 2: Diagnosis of COPD and reversibility tests.
ERS NICE GOLD
COPD diagnosis using only FVC (%) 17.6 10.2 14.0
COPD diagnosis using best value of SVC and FVC (%) 21.7 11.7 16.8
Reversibility among subjects with COPD (according to ERS, NICE and GOLD guidelines using the best of SVC and FVC)
N 861 446 652
Percent of predicted (mean; 95%CI) 4.8 (4.4–5.1) 5.5 (5.0–6.0) 3.7 (3.3–4.2)
Percent of pre-bronchodilator (mean; 95%CI) 6.9 (6.3–7.5) 9.2 (8.3–10.1) 6.0 (5.3–6.7)
COPD according to the NICE, GOLD and ERS guidelines in 3887 smokers who were smoking more than 8 cigarettes per day at the time of the 
trial. The prevalence has been calculated using either FVC or the best of FVC and SVC. Figures in bold indicate the analysis which is recommended 
in the guidelines, respectively. The table is also showing reversibility after inhalation of 0.8 mg of salbutamol as percent of predicted value and as 
percent of pre-bronchodilator value.
A. Slow (SVC) and forced vital capacity (FVC) before bron- chodilatation in 3887 smokers and pre- and post-bronchodil- atation in 1577 smokers with a pre-bronchodilator FEV1/VC- ratio below 0.75 Figure 2
A. Slow (SVC) and forced vital capacity (FVC) before bron-
chodilatation in 3887 smokers and pre- and post-bronchodil-
atation in 1577 smokers with a pre-bronchodilator FEV1/VC-
ratio below 0.75. B. The difference between SVC and FVC 
corrected for VC-level in the same smokers as in panel A.
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thus highly dependent on which guidelines the diagnosis
was based but also on the measurement of vital capacity.
If only FVC was measured the prevalence of COPD was up
to 4.1 percentage units lower than if a slow SVC also was
measured and the best value of SVC and FVC was chosen
for the FEV1/vital capacity ratio.
The main reason for the large difference in the prevalence
of COPD between the ERS and NICE definitions is that
the NICE guidelines require a FEV1 less than 80% of the
predicted value. In the GOLD and the ERS/ATS guidelines
from 2004 post-bronchodilator values are used for calcu-
lation of the FEV1/VC ratio leading to a lower prevalence
of COPD than if the ERS definition is applied. The exclu-
sion of persons with a low FEV1/VC ratio, implying airway
obstruction, but with a FEV1 within two standard residuals
of the predicted mean, is probably justified in a clinical
setting. For epidemiological or preventive purposes this
exclusion of a vast number of persons with mild COPD is
more doubtful. In all three guidelines the importance of
early detection and active smoking intervention is empha-
sized and it therefore seems prudent to also include mild
disease (as in ERS and GOLD) in the definition of COPD
in order to intensify the efforts of smoking cessation. The
population impact of different definitions of airway
obstruction has been described by Celli and coworkers [9]
and our results further stress the need for a clear definition
of chronic obstructive pulmonary disease for both epide-
miological and clinical purposes.
In the NICE and GOLD guidelines, obstruction is defined
as a FEV1/FVC ratio < 0.7. The ERS defines COPD as FEV1/
(FVC or SVC) < 88% predicted value in men and < 89% of
predicted value in women (i.e. > 1.64 residual standard
deviation below predicted value). Since the predicted
value of FEV1/SVC declines with age and the limit is
higher for women (89% of predicted), the COPD diagno-
sis according to the ERS-definition, will include young
females and exclude older men to a greater extent than the
NICE and the GOLD definitions. This limitation of the
GOLD criteria (in particular) for diagnosing COPD in eld-
erly people has been described by Hardie and coworkers
[10]. An important clinical implication of this is that the
diagnosis of COPD may be delayed in women when the
GOLD and NICE guidelines are used instead of the ERS
recommendations. This is particularly contentious since
A. Difference between pre-bronchodilator slow (SVC) and forced (FVC) vital capacity related to FEV1 as percent of predicted  value prior to bronchodilatation in 3881 smokers Figure 4
A. Difference between pre-bronchodilator slow (SVC) and forced (FVC) vital capacity related to FEV1 as percent of predicted 
value prior to bronchodilatation in 3881 smokers. Due to difficulties in taking instructions or technical errors data from 6 
spirometries were not included in the analyses which thus are based on 3881 and not 3887 smokers. B. Difference between 
post-bronchodilator slow (SVC) and forced (FVC) vital capacity related to FEV1 as percent of predicted value after bronchodil-
atation in 1574 smokers with a pre-bronchodilator FEV1/VC -ratio below 0.75. Due to unacceptable measurements or techni-
cal errors data from 3 spirometries were not included in the analyses which thus is based on 1574 and not 1577 smokers.
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smoking women are more susceptible to COPD [11,12].
In addition, men have a higher success rate in smoking
cessation, which may indicate that more intensive effort is
needed at an earlier stage in guiding women to successful
smoking cessation [13,14].
The way of calculating the FEV1/VC ratio also substantially
influences the prevalence of COPD. The use of either slow
vital capacity (SVC) or forced vital capacity (FVC) is sug-
gested in the ERS consensus statement from 1995 whereas
the GOLD, the NICE and the ATS/ERS guidelines from
2004 only suggest the use of FVC. If the best value of FVC
or SVC is used for the calculation of the FEV1/VC ratio
instead of FVC the prevalence of COPD increases with 10–
20% as shown in the present study. The disadvantage of
using only FVC was greater in men and persons with
impaired lungfuction (low VC and FEV1). Although this
disadvantage diminished after bronchodilatation, it
remained and could therefore not be neglected. The clini-
cal implication of this is that a diagnosis of COPD may be
overlooked if SVC is not performed, a risk that seems to be
especially high in men with mild disease. Several papers
have been published describing the differences between
the FVC and the slow SVC in small groups of patients (<
100) with chronic airways obstruction [15-17] but the
present study is the first using a large population dataset.
The reversibility to a bronchodilator (salbutamol) in the
COPD patients was somewhat different depending on
how COPD was defined. The NICE guidelines require a
FEV1 below 80% of predicted value which reduces the
number of positive diagnosis but, as these patients have a
lower pre-bronchodilator FEV1, leave a greater space for
increase following inhalation of a bronchodilator.
Conclusion
Uniform international standards for the diagnosis of
COPD are lacking. The existing major consensus state-
ments and guidelines, regarding the diagnosis of COPD,
yield differences in prevalence rates, which perhaps reflect
that the different guidelines may primarily be intended
for either clinical use or for screening and prevention. This
complicates the organization of appropriate epidemiolog-
ical surveys and comparisons between countries. Our
results indicate that both the FVC and the SVC manoeuvre
should be performed when persons at risk for COPD are
examined. We also fully agree with the generally accepted
concept to diagnose COPD based on lung function meas-
urements after bronchodilatation.
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